Compass Therapeutics, Inc. (CMPX)
2.52
+0.12
(+5.00%)
USD |
NASDAQ |
Aug 25, 16:00
2.50
-0.02
(-0.79%)
After-Hours: 18:11
Compass Therapeutics Debt to Equity Ratio : 0.058 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.058 |
| March 31, 2026 | 0.0525 |
| December 31, 2025 | 0.0499 |
| September 30, 2025 | 0.0471 |
| June 30, 2025 | 0.1063 |
| March 31, 2025 | 0.0579 |
| December 31, 2024 | 0.053 |
| September 30, 2024 | 0.0497 |
| June 30, 2024 | 0.0074 |
| March 31, 2024 | 0.009 |
| December 31, 2023 | 0.0117 |
| September 30, 2023 | 0.0128 |
| June 30, 2023 | 0.0139 |
| March 31, 2023 | 0.0151 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0162 |
| September 30, 2022 | 0.0277 |
| June 30, 2022 | 0.0275 |
| March 31, 2022 | 0.028 |
| December 31, 2021 | 0.0288 |
| September 30, 2021 | 0.341 |
| June 30, 2021 | 0.3555 |
| March 31, 2021 | 0.3698 |
| December 31, 2020 | 0.2337 |
| September 30, 2020 | 0.2367 |
| June 30, 2020 | 0.245 |
| March 31, 2020 | -1.160 |
| December 31, 2019 | -1.220 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Upstream Bio, Inc. | 0.0035 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 190.17M |
| Total Liabilities (Quarterly) | 24.12M |
| Shareholders Equity (Quarterly) | 166.05M |
| Current Ratio | 11.22 |
| Net Debt Paydown Yield | -0.16% |